SI2536746T1 - Z disulfidno vezjo-stabilizirani funkcionalni topni heterodimeri mhc razreda ii - Google Patents

Z disulfidno vezjo-stabilizirani funkcionalni topni heterodimeri mhc razreda ii

Info

Publication number
SI2536746T1
SI2536746T1 SI201130815A SI201130815A SI2536746T1 SI 2536746 T1 SI2536746 T1 SI 2536746T1 SI 201130815 A SI201130815 A SI 201130815A SI 201130815 A SI201130815 A SI 201130815A SI 2536746 T1 SI2536746 T1 SI 2536746T1
Authority
SI
Slovenia
Prior art keywords
heterodimers
mhc class
disulphide bond
soluble mhc
functional soluble
Prior art date
Application number
SI201130815A
Other languages
English (en)
Slovenian (sl)
Inventor
Geir Age Loset
Terje Frigstad
Inger Sandlie
Bjarne Bogen
Original Assignee
Universitetet I Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet I Oslo filed Critical Universitetet I Oslo
Publication of SI2536746T1 publication Critical patent/SI2536746T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
SI201130815A 2010-02-18 2011-02-18 Z disulfidno vezjo-stabilizirani funkcionalni topni heterodimeri mhc razreda ii SI2536746T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30572810P 2010-02-18 2010-02-18
GBGB1002730.8A GB201002730D0 (en) 2010-02-18 2010-02-18 Product
US31657610P 2010-03-23 2010-03-23
PCT/GB2011/050325 WO2011101681A2 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers
EP11730044.2A EP2536746B1 (en) 2010-02-18 2011-02-18 Disulphide bond-stabilized functional soluble mhc class ii heterodimers

Publications (1)

Publication Number Publication Date
SI2536746T1 true SI2536746T1 (sl) 2016-09-30

Family

ID=42113985

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130815A SI2536746T1 (sl) 2010-02-18 2011-02-18 Z disulfidno vezjo-stabilizirani funkcionalni topni heterodimeri mhc razreda ii

Country Status (18)

Country Link
US (2) US8828379B2 (https=)
EP (1) EP2536746B1 (https=)
JP (1) JP5537675B2 (https=)
KR (1) KR101647176B1 (https=)
CN (1) CN102947330B (https=)
AU (1) AU2011217027B2 (https=)
CA (1) CA2789492C (https=)
CY (1) CY1117697T1 (https=)
DK (1) DK2536746T3 (https=)
ES (1) ES2572388T3 (https=)
GB (1) GB201002730D0 (https=)
HR (1) HRP20160475T1 (https=)
HU (1) HUE027952T2 (https=)
PL (1) PL2536746T3 (https=)
RS (1) RS54744B1 (https=)
RU (1) RU2604813C2 (https=)
SI (1) SI2536746T1 (https=)
WO (1) WO2011101681A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP4592400A3 (en) 2012-10-17 2025-10-29 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP6748061B2 (ja) * 2014-07-09 2020-08-26 ルピン・リミテッド 二重シストロン細菌発現システム
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
US12577289B2 (en) 2015-06-30 2026-03-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Surrogate co-receptors for t cells and methods of use
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
EP4345453B1 (en) * 2018-09-28 2025-11-12 10X Genomics, Inc. High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3719033A1 (en) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
US20220409732A1 (en) * 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
DE102020109447A1 (de) 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein
US12534510B2 (en) 2020-04-16 2026-01-27 The Regents Of The University Of California Peptide-receptive MHC-I complex compositions and methods
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2025137580A1 (en) * 2023-12-22 2025-06-26 Antiger Therapeutics, Inc. Class ii hla with inter-chain disulfide bond

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
JP2000516470A (ja) * 1996-08-16 2000-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 可溶性一価および多価mhcクラスii融合タンパク質およびそれらの使用
CA2302779C (en) * 1997-09-16 2010-02-02 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
US8377447B2 (en) * 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CA2638892A1 (en) 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
JP5154564B2 (ja) * 2006-12-01 2013-02-27 カール・ツァイス・エスエムティー・ゲーエムベーハー 像収差を低減するための交換可能で操作可能な補正構成を有する光学システム
ES2445152T3 (es) 2007-08-20 2014-02-28 Nextera As Presentación en fagos de pVII

Also Published As

Publication number Publication date
KR20130009782A (ko) 2013-01-23
GB201002730D0 (en) 2010-04-07
WO2011101681A2 (en) 2011-08-25
JP5537675B2 (ja) 2014-07-02
AU2011217027B2 (en) 2015-02-05
CA2789492C (en) 2017-04-18
ES2572388T3 (es) 2016-05-31
KR101647176B1 (ko) 2016-08-09
US8828379B2 (en) 2014-09-09
PL2536746T3 (pl) 2016-08-31
RS54744B1 (sr) 2016-10-31
RU2012138302A (ru) 2014-03-27
RU2604813C2 (ru) 2016-12-10
WO2011101681A3 (en) 2011-12-08
US20130171668A1 (en) 2013-07-04
US9056920B2 (en) 2015-06-16
JP2013519721A (ja) 2013-05-30
HUE027952T2 (en) 2016-11-28
EP2536746A2 (en) 2012-12-26
US20140349315A1 (en) 2014-11-27
HRP20160475T1 (hr) 2016-06-03
CN102947330B (zh) 2015-09-16
CY1117697T1 (el) 2017-05-17
CA2789492A1 (en) 2011-08-25
AU2011217027A1 (en) 2012-09-06
EP2536746B1 (en) 2016-04-20
CN102947330A (zh) 2013-02-27
DK2536746T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PL2536746T3 (pl) Stabilizowane wiązaniem disulfidowym funkcjonalne rozpuszczalne heterodimery mhc klasy ii
EP2575702A4 (en) orthotic device
EP2596765A4 (en) STENT DEVICE
EP2610112A4 (en) Wire harness
GB201301684D0 (en) Early entry
EP2579826A4 (en) CONDOM
GB2479429B (en) Attachment device
BR112013009020A2 (pt) bolsa de ostomia
GB201117661D0 (en) Early entry
PL2523878T3 (pl) Urządzenie przenośnikowe
IL220850A0 (en) Pigmentation-preventing or-ameliorating agent
BR112013010757A2 (pt) bolsa de ostomia
EP2564149A4 (en) PYROTECHNIC DEVICE
ZA201105607B (en) Animal ectoparasite-controlling agent
ZA201105609B (en) Animal ectoparasite-controlling agent
EP2609927A4 (en) CELL PROTECTION PRODUCTS
ZA201105606B (en) Animal ectoparasite-controlling agent
ZA201105608B (en) Animal ectoparasite-controlling agent
GB201014041D0 (en) Soluble film
PL2385003T3 (pl) Urządzenie przenośnikowe
PL2566419T3 (pl) Orteza
GB201113204D0 (en) Orthotic device
GB201120098D0 (en) Early entry
GB201010748D0 (en) Platform extension
HK1177939A (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers